Daily Archives: January 18, 2018

Approximately 1/3rd of the patients with ulcerative colitis (UC) and 70% of those with Crohn’s disease (CD) undergo surgery over their lifetime. Nutritional optimization is a cornerstone of successful surgical outcomes in inflammatory bowel disease (… Continue reading →

While phase II-III trials clearly demonstrated efficacy of tofacitinib, an oral small molecule pan-JAK inhibitor, in patients with UC, in CD tofacitinib did not differ from placebo, raising questions about the design of those trials but also about tofa… Continue reading →

Tumor necrosis factor inhibitors (TNFi) are effective treatments for ulcerative colitis (UC). The TNFi certolizumab pegol (CZP) is effective in Crohn’s disease, and an open label (OL) study suggested that CZP is effective for induction of response in… Continue reading →

Many factors about low bone mineral density (BMD) in patients with inflammatory bowel disease (IBD) have been reported. Continue reading →

IBD therapeutic endpoints have evolved over time with the addition of mucosal healing (MH) as a treatment goal. Adult data suggest patients who achieve MH have improved outcomes but pediatric data is lacking. The aims of our study was to evaluate the r… Continue reading →

Vedolizumab (VDZ) and infliximab (IFX) are both approved as first line induction agents in moderately to severely active UC. However, there are no head-to-head studies comparing the relative effectiveness of the two. Here we provide a real-world compar… Continue reading →

Perianal disease including perianal fistula and perianal abscess is known as one of the poor prognostic factors of Crohn’s disease (CD). However, there has been no tool for CD patients to check their perianal symptoms. We aimed to develop self-screen… Continue reading →

Infliximab and vedolizumab infusions pose a burden to inflammatory bowel disease (IBD) patients due to the need to travel and take time from work. To minimize burden, home infusions are available for selected patients. We aimed to describe the populati… Continue reading →

Treatments for Crohn’s disease (CD) or ulcerative colitis (UC) include anti-TNFs and novel therapies, but optimal real-world treatment sequencing has not been well-studied. This study compared healthcare resource use (HRU) and costs associated with s… Continue reading →

Rates of surgical recurrence after curative intestinal resection for Crohn’s disease are high. It is unclear whether early initiation of postoperative prophylaxis is efficacious in preventing surgical recurrence. Continue reading →